WO2002058622A3 - Sn-38 lipid complexes and methods of use - Google Patents

Sn-38 lipid complexes and methods of use Download PDF

Info

Publication number
WO2002058622A3
WO2002058622A3 PCT/US2001/043325 US0143325W WO02058622A3 WO 2002058622 A3 WO2002058622 A3 WO 2002058622A3 US 0143325 W US0143325 W US 0143325W WO 02058622 A3 WO02058622 A3 WO 02058622A3
Authority
WO
WIPO (PCT)
Prior art keywords
complexes
methods
compositions
lipid complexes
present
Prior art date
Application number
PCT/US2001/043325
Other languages
French (fr)
Other versions
WO2002058622A2 (en
Inventor
Imran Ahmad
Jia-Ai Allen Zhang
Aquilur Rahman
Original Assignee
Neopharm Inc
Imran Ahmad
Jia-Ai Allen Zhang
Aquilur Rahman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SK709-2003A priority Critical patent/SK7092003A3/en
Priority to CA002427467A priority patent/CA2427467C/en
Priority to MXPA03004095A priority patent/MXPA03004095A/en
Priority to HU0302352A priority patent/HUP0302352A3/en
Priority to EP01994079A priority patent/EP1355634B8/en
Priority to DE60136490T priority patent/DE60136490D1/en
Priority to AU2002246510A priority patent/AU2002246510B2/en
Application filed by Neopharm Inc, Imran Ahmad, Jia-Ai Allen Zhang, Aquilur Rahman filed Critical Neopharm Inc
Priority to PL01363618A priority patent/PL363618A1/en
Priority to BR0115260-2A priority patent/BR0115260A/en
Priority to KR1020037006195A priority patent/KR100869824B1/en
Priority to JP2002558957A priority patent/JP4524071B2/en
Priority to NZ525552A priority patent/NZ525552A/en
Priority to IL15569601A priority patent/IL155696A0/en
Priority to EA200300550A priority patent/EA006741B1/en
Publication of WO2002058622A2 publication Critical patent/WO2002058622A2/en
Priority to US10/424,258 priority patent/US7390502B2/en
Priority to NO20032069A priority patent/NO20032069L/en
Priority to BG107862A priority patent/BG107862A/en
Publication of WO2002058622A3 publication Critical patent/WO2002058622A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention is for novel compositions and methods for treating diseases caused by cellular proliferation, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include SN-38 lipid complexes in which the complexes can contain any of a variety of neutral or charged lipids and, desirably, cardiolipin. The compositions are capable of efficiently incorporating SN-38 into complexes and are capable of solubilizing relatively high concentrations of SN-38.
PCT/US2001/043325 2000-11-09 2001-11-09 Sn-38 lipid complexes and methods of use WO2002058622A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
IL15569601A IL155696A0 (en) 2000-11-09 2001-11-09 Sn-38 lipid complexes and methods of use
MXPA03004095A MXPA03004095A (en) 2000-11-09 2001-11-09 Sn-38 lipid complexes and methods of use.
HU0302352A HUP0302352A3 (en) 2000-11-09 2001-11-09 Sn-38 lipid complexes and methods of use
EP01994079A EP1355634B8 (en) 2000-11-09 2001-11-09 Sn-38 lipid complexes and methods of use
DE60136490T DE60136490D1 (en) 2000-11-09 2001-11-09 SN-38 LIPID COMPLEXES AND METHOD OF USE THEREOF
AU2002246510A AU2002246510B2 (en) 2000-11-09 2001-11-09 SN-38 lipid complexes and methods of use
KR1020037006195A KR100869824B1 (en) 2000-11-09 2001-11-09 38 lipid complexes and methods of use
PL01363618A PL363618A1 (en) 2000-11-09 2001-11-09 Sn-38 lipid complexes and methods of use
BR0115260-2A BR0115260A (en) 2000-11-09 2001-11-09 Sn-38 lipid complexes and their uses in treating diseases
SK709-2003A SK7092003A3 (en) 2000-11-09 2001-11-09 SN-38 lipid complexes and methods of use
JP2002558957A JP4524071B2 (en) 2000-11-09 2001-11-09 SN-38 lipid complex and method of use
NZ525552A NZ525552A (en) 2000-11-09 2001-11-09 SN-38 lipid complexes with cardiolipin and methods of use for the treatment of cancers and multiple sclerosis
CA002427467A CA2427467C (en) 2000-11-09 2001-11-09 Sn-38 lipid complexes and methods of use
EA200300550A EA006741B1 (en) 2000-11-09 2001-11-09 Peptide composition comprising camptothecin derivative (variants), method for manufacturing thereof and use
US10/424,258 US7390502B2 (en) 2000-11-09 2003-04-28 SN-38 lipid complexes and their methods of use
NO20032069A NO20032069L (en) 2000-11-09 2003-05-08 SN-38 Lipid Complexes and Method for Using Them
BG107862A BG107862A (en) 2000-11-09 2003-05-30 Sn-38 lipid complexes and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24730600P 2000-11-09 2000-11-09
US60/247,306 2000-11-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/424,258 Continuation US7390502B2 (en) 2000-11-09 2003-04-28 SN-38 lipid complexes and their methods of use

Publications (2)

Publication Number Publication Date
WO2002058622A2 WO2002058622A2 (en) 2002-08-01
WO2002058622A3 true WO2002058622A3 (en) 2003-08-28

Family

ID=22934406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/043325 WO2002058622A2 (en) 2000-11-09 2001-11-09 Sn-38 lipid complexes and methods of use

Country Status (22)

Country Link
US (1) US7390502B2 (en)
EP (1) EP1355634B8 (en)
JP (1) JP4524071B2 (en)
KR (1) KR100869824B1 (en)
CN (1) CN1531424A (en)
AT (1) ATE413164T1 (en)
AU (1) AU2002246510B2 (en)
BG (1) BG107862A (en)
BR (1) BR0115260A (en)
CA (1) CA2427467C (en)
CZ (1) CZ20031515A3 (en)
DE (1) DE60136490D1 (en)
EA (1) EA006741B1 (en)
HU (1) HUP0302352A3 (en)
IL (1) IL155696A0 (en)
MX (1) MXPA03004095A (en)
NO (1) NO20032069L (en)
NZ (1) NZ525552A (en)
PL (1) PL363618A1 (en)
SK (1) SK7092003A3 (en)
WO (1) WO2002058622A2 (en)
ZA (1) ZA200303432B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7262173B2 (en) 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
WO2003018018A2 (en) * 2001-08-24 2003-03-06 Neopharm, Inc. Vinorelbine compositions and methods of use
WO2003039600A1 (en) * 2001-11-09 2003-05-15 Neopharm, Inc. Selective treatment of il-13 expressing tumors
US7138512B2 (en) * 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
EA200401565A1 (en) * 2002-05-24 2005-04-28 Неофарм, Инк. METHOD FOR OBTAINING CARDIOLYPINE OR ANALOGUE OF CARDIOLIPINE (OPTIONS), METHOD FOR OBTAINING LIPOSOME AND COMPOSITION OF CARDIOLIPINE FOR TREATING DISEASES (OPTIONS)
WO2003099830A2 (en) * 2002-05-24 2003-12-04 Neopharm, Inc. Cardiolipin compositions, methods of preparation and use
AU2003240934A1 (en) * 2002-05-29 2003-12-19 Neopharm, Inc. Method for determining oligonucleotide concentration
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
AU2003268087A1 (en) * 2002-08-23 2004-03-11 Ian Ma Liposomal gemcitabine compositions for better drug delivery
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
EP1596825A2 (en) * 2003-02-03 2005-11-23 Neopharm, Inc. Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs
EA200501285A1 (en) * 2003-02-11 2006-02-24 Неофарм, Инк. METHOD OF OBTAINING LIPOSOMAL DRUGS
WO2004087758A2 (en) * 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
EP1643971A2 (en) * 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
US20060078560A1 (en) * 2003-06-23 2006-04-13 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis
KR100847626B1 (en) * 2004-06-18 2008-07-21 테루모 가부시키가이샤 Liposome preparation containing slightly water-soluble camptothecin
EP1793833A1 (en) * 2004-09-15 2007-06-13 Vasogen Ireland Limited Multiple sclerosis treatment
EP2081548A2 (en) * 2006-09-22 2009-07-29 Labopharm Inc. Compositions and methods for ph targeted drug delivery
EP2086513B1 (en) 2006-09-26 2016-09-07 Samyang Biopharmaceuticals Corporation Submicron nanoparticle of poorly water soluble camptothecin derivatives and process for preparation thereof
DK2076244T3 (en) * 2006-10-10 2017-02-27 Jina Pharmaceuticals Inc Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods and uses thereof
WO2008058156A2 (en) 2006-11-06 2008-05-15 Jina Pharmaceuticals Inc. Guggulphospholipid methods and compositions
US8067432B2 (en) * 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
WO2010045199A2 (en) * 2008-10-13 2010-04-22 University Of South Florida Method of modulating ship activity
KR20120094546A (en) * 2009-05-04 2012-08-24 인터자인 테크놀로지스, 인코포레이티드 Polymer micelles containing sn-38 for the treatment of cancer
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US20110207760A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Sn-38 compositions
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN104856931B (en) * 2014-02-24 2019-06-18 石药集团中奇制药技术（石家庄）有限公司 A kind of amphotericin B nano compound and preparation method thereof
CN106132422A (en) 2014-02-27 2016-11-16 莱斯拉公司 Use the adoptive cellular therapy ＆ related methods for the treatment of of the agonist of retinoic acid receptors related orphan receptor y
WO2015171610A2 (en) 2014-05-05 2015-11-12 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
AU2016257997A1 (en) 2015-05-05 2017-11-09 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
AU2016276947A1 (en) 2015-06-11 2017-12-14 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
CN110302171A (en) * 2019-07-12 2019-10-08 山东大学 A kind of intratumor injection SN-38-PLGA sustained-release micro-spheres and its preparation method and application
US11286344B2 (en) 2020-01-10 2022-03-29 Tyndall Formulation Services, LLC Polymer excipients for drug delivery applications
US11857630B2 (en) * 2020-01-10 2024-01-02 Tyndall Formulation Services, LLC Formulations of SN-38 with poly(amino acid) block polymers
CN117098536A (en) * 2021-10-15 2023-11-21 昆山新蕴达生物科技有限公司 Composition containing antitumor drug and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834012A (en) * 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS180644B2 (en) 1973-09-29 1978-01-31 Takeda Chemical Industries Ltd Process for preparing nonapeptides
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4115544A (en) 1976-08-18 1978-09-19 Alza Corporation Ocular system made of bioerodible esters having linear ether
GB1575343A (en) 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
CH621479A5 (en) 1977-08-05 1981-02-13 Battelle Memorial Institute
CH624011A5 (en) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
CA1173360A (en) 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
HU184141B (en) 1979-12-27 1984-07-30 Human Oltoanyagtermelo Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4419348A (en) 1981-04-27 1983-12-06 Georgetown University Anthracycline glycoside compositions, their use and preparation
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4721612A (en) 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
EP0208764A4 (en) * 1985-01-11 1987-10-08 Univ California Method for preserving liposomes.
US4857319A (en) 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
US5187167A (en) 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
US4812312A (en) 1987-03-03 1989-03-14 Board Of Regents Of The University Of Texas System Liposome-incorporated nystatin
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
JP2780755B2 (en) * 1987-05-22 1998-07-30 ザ リポソーム カンパニー，インコーポレイテッド Prostaglandin-lipid preparation
GB8727737D0 (en) 1987-11-26 1987-12-31 Ici Plc Antitumour agents
MX9203504A (en) 1988-04-20 1992-07-01 Liposome Co Inc AGENT COMPLEX: HIGH PROPORTION ACTIVE LIPID.
US4952408A (en) 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US5077057A (en) 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5003097A (en) 1989-10-02 1991-03-26 The United States Of America As Represented By The Department Of Health And Human Services Method for the sulfurization of phosphorous groups in compounds
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US5389377A (en) 1989-12-22 1995-02-14 Molecular Bioquest, Inc. Solid care therapeutic compositions and methods for making same
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
US5422344A (en) 1990-05-08 1995-06-06 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Method of treating retroviral infections in mammals
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5603872A (en) * 1991-02-14 1997-02-18 Baxter International Inc. Method of binding recognizing substances to liposomes
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
DE69329073T2 (en) 1992-03-23 2001-01-18 Georgetown University Washingt TAXOL ENCLOSED IN LIPOSOMES AND METHOD OF USE
US5391745A (en) 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
WO1994005259A1 (en) 1992-09-02 1994-03-17 Georgetown University Method of encapsulating anthracycline glycosides in liposomes
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5527913A (en) 1993-02-25 1996-06-18 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds
US5352789A (en) 1993-02-25 1994-10-04 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds
US5776486A (en) 1993-05-28 1998-07-07 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
US5405963A (en) 1993-06-10 1995-04-11 Smithkline Beecham Corporation Process for asymmetric total synthesis of camptothecin analogues
US5475108A (en) 1993-08-31 1995-12-12 North Carolina State University Camptothecin intermediates and method of making camptothecin and comptothecin analogs
JPH09504517A (en) * 1993-09-27 1997-05-06 スミスクライン・ビーチャム・コーポレイション Camptothecin formulation
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
JP2828391B2 (en) * 1993-10-29 1998-11-25 東燃株式会社 Liposomes with oligosaccharides on the surface
US5447936A (en) 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5786344A (en) 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
ATE380559T1 (en) 1994-08-19 2007-12-15 Wallone Region CONJUGATES CONTAINING AN ANTITUMORAL AGENT AND USE THEREOF
US5776743A (en) 1994-09-06 1998-07-07 La Jolla Cancer Research Foundation Method of sensitizing tumor cells with adenovirus E1A
US5496830A (en) 1994-09-14 1996-03-05 Johns Hopkins University Inhibition of hemoflagellates by camptothecin compounds
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5736156A (en) 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5972955A (en) 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
WO1997019085A1 (en) 1995-11-22 1997-05-29 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
GB9601779D0 (en) 1996-01-30 1996-04-03 Pharmacia Spa 9, 10 Disubstituted camptothecin derivatives
US5759767A (en) 1996-10-11 1998-06-02 Joseph R. Lakowicz Two-photon and multi-photon measurement of analytes in animal and human tissues and fluids
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
SG88737A1 (en) 1996-10-30 2002-05-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US6559129B1 (en) * 1997-03-21 2003-05-06 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US7262173B2 (en) * 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US20030229040A1 (en) * 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
NZ503293A (en) * 1997-09-16 2002-09-27 Nexstar Pharmaceuticals Inc Liposomal camptothecin formulations also comprising at least one phospholipid
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6183958B1 (en) 1998-05-06 2001-02-06 Variagenics, Inc. Probes for variance detection
JP2002518022A (en) 1998-06-16 2002-06-25 ノヴァ モレキュラー インク． Method for treating neurological diseases by determining BCHE genotype
US6146659A (en) 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6461637B1 (en) * 2000-09-01 2002-10-08 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6664062B1 (en) * 1998-07-20 2003-12-16 Nuvelo, Inc. Thymidylate synthase gene sequence variances having utility in determining the treatment of disease
CA2346879A1 (en) * 1998-09-16 2000-04-27 Alza Corporation Liposome-entrapped topoisomerase inhibitors
US6610492B1 (en) * 1998-10-01 2003-08-26 Variagenics, Inc. Base-modified nucleotides and cleavage of polynucleotides incorporating them
US6500650B1 (en) * 1998-10-01 2002-12-31 Variagenics, Inc. Method for identifying polymorphisms
US6458945B1 (en) * 1998-10-01 2002-10-01 Variagenics, Inc. Method for analyzing polynucleotides
US6777188B2 (en) * 1998-10-01 2004-08-17 Variagenics, Inc. Genotyping by mass spectrometric analysis of allelic fragments
CA2354544A1 (en) * 1998-10-01 2000-04-13 Variagenics, Inc. Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
US6686148B1 (en) * 1999-03-01 2004-02-03 Nuvelo, Inc. Methods for targeting RNA molecules
US6291676B1 (en) * 1999-03-03 2001-09-18 University Of Kentucky Research Foundation Water-soluble derivatives of camptothecin/homocamptothecin
US6573049B1 (en) * 1999-07-26 2003-06-03 Nuvelo, Inc. Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
US6475736B1 (en) * 2000-05-23 2002-11-05 Variagenics, Inc. Methods for genetic analysis of DNA using biased amplification of polymorphic sites
CA2424345A1 (en) * 2000-10-16 2002-04-25 Neopharm, Inc. Liposomal formulation of mitoxantrone
WO2002059337A1 (en) * 2001-01-26 2002-08-01 Georgetown University School Of Medicine Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
WO2003039600A1 (en) * 2001-11-09 2003-05-15 Neopharm, Inc. Selective treatment of il-13 expressing tumors
US7138512B2 (en) * 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) * 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
AU2003228238A1 (en) * 2002-05-20 2003-12-12 Neopharm, Inc. Method for reducing platelet count
US20030228317A1 (en) * 2002-05-22 2003-12-11 Prafulla Gokhale Gene BRCC-1 and diagnostic and therapeutic uses thereof
WO2003099830A2 (en) * 2002-05-24 2003-12-04 Neopharm, Inc. Cardiolipin compositions, methods of preparation and use
EA200401565A1 (en) * 2002-05-24 2005-04-28 Неофарм, Инк. METHOD FOR OBTAINING CARDIOLYPINE OR ANALOGUE OF CARDIOLIPINE (OPTIONS), METHOD FOR OBTAINING LIPOSOME AND COMPOSITION OF CARDIOLIPINE FOR TREATING DISEASES (OPTIONS)
AU2003240934A1 (en) * 2002-05-29 2003-12-19 Neopharm, Inc. Method for determining oligonucleotide concentration
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
AU2003268087A1 (en) * 2002-08-23 2004-03-11 Ian Ma Liposomal gemcitabine compositions for better drug delivery
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834012A (en) * 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation

Also Published As

Publication number Publication date
EP1355634A2 (en) 2003-10-29
AU2002246510B2 (en) 2007-09-20
JP2004529086A (en) 2004-09-24
EA200300550A1 (en) 2004-06-24
JP4524071B2 (en) 2010-08-11
CZ20031515A3 (en) 2003-09-17
DE60136490D1 (en) 2008-12-18
CA2427467A1 (en) 2002-08-01
EA006741B1 (en) 2006-04-28
US20030215492A1 (en) 2003-11-20
BR0115260A (en) 2005-08-16
EP1355634B8 (en) 2009-03-04
CA2427467C (en) 2010-01-12
IL155696A0 (en) 2003-11-23
MXPA03004095A (en) 2004-09-10
PL363618A1 (en) 2004-11-29
KR100869824B1 (en) 2008-11-21
NO20032069D0 (en) 2003-05-08
WO2002058622A2 (en) 2002-08-01
KR20030072352A (en) 2003-09-13
NZ525552A (en) 2005-04-29
EP1355634B1 (en) 2008-11-05
BG107862A (en) 2004-06-30
EP1355634A4 (en) 2005-07-06
AU2002246510A2 (en) 2002-08-06
HUP0302352A2 (en) 2003-11-28
ZA200303432B (en) 2004-08-05
CN1531424A (en) 2004-09-22
ATE413164T1 (en) 2008-11-15
HUP0302352A3 (en) 2007-03-28
US7390502B2 (en) 2008-06-24
NO20032069L (en) 2003-07-02
SK7092003A3 (en) 2004-06-08

Similar Documents

Publication Publication Date Title
WO2002058622A3 (en) Sn-38 lipid complexes and methods of use
AU2002341920A1 (en) Chemical compounds
EP1352897A3 (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
CY1106816T1 (en) 3,4-DIHYDRO-1H-PYRIMIDE [4,5-D] PYRIMIDIN-2-ONE 1,5-DISUBTITUTED COMPOUNDS AND THEIR USE FOR THE THERAPEUTIC TREATMENT OF DISEASES MEDIATED BY CSBP/P38 KINASE
WO2004034990A3 (en) Methods and compositions for use in treating cancer
IL192339A0 (en) NOVEL 2,4,8-TRISUBSTITUTED-8H- PYRIDO[2,3-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/P38 KINASE MEDIATED DISEASES
ZA200306886B (en) Pyrazolopyrimidines as therapeutic agents.
WO2003024395A8 (en) Linked biaryl compounds
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002040000A3 (en) Use of cci-779 as an antineoplastic agent
MXPA04002682A (en) Substituted pyrazolo compounds for the treatment of inflammation.
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
WO2000066528A3 (en) Quinones for treatment of diseases
AU2002358199A1 (en) Shorts or underpants retaining the sexual organs
AU2002350623A1 (en) Targeted thrombosis by tissue factor polypeptides
NZ335125A (en) Carriers containing an etherlipid/complementarily shape lipid combination and therapeutic uses thereof
WO2001062239A3 (en) Novel compositions and uses of dictyostatin compounds
WO2003035032A3 (en) New non-phospholipid lipid vesicles (nplv) and their use in cosmetic, therapeutic and prophylactic applications
PT1303520E (en) Therapeutic compounds and methods
AU2002360350A1 (en) Peptides that home to tumor lymphatic vasculature and methods of using same
WO2000009071A3 (en) A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
EP1436279A4 (en) Chemical compounds
AU2001296224A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2004089302A3 (en) Posh polypeptides, complexes and related methods
WO2003020371A3 (en) Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10424258

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2427467

Country of ref document: CA

Ref document number: 525552

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 155696

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003/03432

Country of ref document: ZA

Ref document number: 200303432

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020037006195

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002558957

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/004095

Country of ref document: MX

Ref document number: 018186351

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PV2003-1515

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 7092003

Country of ref document: SK

Ref document number: 2001994079

Country of ref document: EP

Ref document number: 2002246510

Country of ref document: AU

Ref document number: 883/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200300550

Country of ref document: EA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 1020037006195

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2003-1515

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001994079

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 525552

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 525552

Country of ref document: NZ